Source:http://linkedlifedata.com/resource/pubmed/id/21536448
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
2011-5-25
|
pubmed:abstractText |
Amino-bisphosphonates (alendronate, pamidronate) were covalently linked in a three step synthesis, with protected and triazolylated derivatives of therapeutically used nucleoside analogs (5-FdU, araC, AZT) by substitution of their triazolyl residue. From the deprotected and chromatographically purified reaction mixtures N?-[alkyl-(hydroxyphosphono) phosphonate]-cytidine combining two differently cytotoxic functions were obtained. This new family of bisphosphonates (BPs) contains as novelty an alkyl side chain with a cytotoxic nucleoside. The BPs moiety allows for a high binding to hydroxyapatite which is a prerequisite for bone targeting of the drugs. In vitro binding of 5-FdU-alendronate (5-FdU-ale) to hydroxyapatite showed a sixfold increased binding of these BPs as compared to 5-FdU. Exploratory cytotoxic properties of 5-FdU-ale were tested on a panel of human tumor cell lines resulting in growth inhibition ranging between 5% and 38%. The determination of IC??-concentrations of the conjugate in Lewis lung carcinoma and murine macrophages showed an incubation time dependent growth inhibition with higher sensitivity towards the tumor cells. We assume that the antimetabolite-BPs can be cleaved into different active metabolites that may exert cytotoxic and other therapeutic effects. However, the underlying mechanisms of these promising new antimetabolite-BPs conjugates remain to be evaluated in future experiments.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/5-fluorouridine,
http://linkedlifedata.com/resource/pubmed/chemical/Alendronate,
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Arabinofuranosyluracil,
http://linkedlifedata.com/resource/pubmed/chemical/Bone Density Conservation Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cytidine,
http://linkedlifedata.com/resource/pubmed/chemical/Diphosphonates,
http://linkedlifedata.com/resource/pubmed/chemical/Durapatite,
http://linkedlifedata.com/resource/pubmed/chemical/Uridine,
http://linkedlifedata.com/resource/pubmed/chemical/Zidovudine,
http://linkedlifedata.com/resource/pubmed/chemical/pamidronate
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
1464-3391
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright © 2011 Elsevier Ltd. All rights reserved.
|
pubmed:issnType |
Electronic
|
pubmed:day |
1
|
pubmed:volume |
19
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
3520-6
|
pubmed:meshHeading |
pubmed-meshheading:21536448-Alendronate,
pubmed-meshheading:21536448-Animals,
pubmed-meshheading:21536448-Antimetabolites, Antineoplastic,
pubmed-meshheading:21536448-Arabinofuranosyluracil,
pubmed-meshheading:21536448-Bone Density Conservation Agents,
pubmed-meshheading:21536448-Bone and Bones,
pubmed-meshheading:21536448-Cell Line, Tumor,
pubmed-meshheading:21536448-Cytidine,
pubmed-meshheading:21536448-Diphosphonates,
pubmed-meshheading:21536448-Drug Screening Assays, Antitumor,
pubmed-meshheading:21536448-Durapatite,
pubmed-meshheading:21536448-Humans,
pubmed-meshheading:21536448-Macrophages,
pubmed-meshheading:21536448-Mice,
pubmed-meshheading:21536448-Uridine,
pubmed-meshheading:21536448-Zidovudine
|
pubmed:year |
2011
|
pubmed:articleTitle |
N?-[Alkyl-(hydroxyphosphono)phosphonate]-cytidine-new drugs covalently linking antimetabolites (5-FdU, araU or AZT) with bone-targeting bisphosphonates (alendronate or pamidronate).
|
pubmed:affiliation |
Institute for Organic Chemistry, University of Tuebingen, Tuebingen, Germany. herbert.schott@uni-tuebingen.de
|
pubmed:publicationType |
Journal Article
|